274 related articles for article (PubMed ID: 35158992)
1. The Application of Metabolomics in Recent Colorectal Cancer Studies: A State-of-the-Art Review.
Gold A; Choueiry F; Jin N; Mo X; Zhu J
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158992
[TBL] [Abstract][Full Text] [Related]
2. Fecal metabolomic profiles: A comparative study of patients with colorectal cancer
Nannini G; Meoni G; Tenori L; Ringressi MN; Taddei A; Niccolai E; Baldi S; Russo E; Luchinat C; Amedei A
World J Gastroenterol; 2021 Oct; 27(38):6430-6441. PubMed ID: 34720532
[TBL] [Abstract][Full Text] [Related]
3. Altered gut metabolites and microbiota interactions are implicated in colorectal carcinogenesis and can be non-invasive diagnostic biomarkers.
Coker OO; Liu C; Wu WKK; Wong SH; Jia W; Sung JJY; Yu J
Microbiome; 2022 Feb; 10(1):35. PubMed ID: 35189961
[TBL] [Abstract][Full Text] [Related]
4. A quantitative multimodal metabolomic assay for colorectal cancer.
Farshidfar F; Kopciuk KA; Hilsden R; McGregor SE; Mazurak VC; Buie WD; MacLean A; Vogel HJ; Bathe OF
BMC Cancer; 2018 Jan; 18(1):26. PubMed ID: 29301511
[TBL] [Abstract][Full Text] [Related]
5. Colorectal Cancer Detection Using Targeted LC-MS Metabolic Profiling.
Djukovic D; Zhang J; Raftery D
Methods Mol Biol; 2018; 1765():229-240. PubMed ID: 29589312
[TBL] [Abstract][Full Text] [Related]
6. Colorectal Cancer Stage-Specific Fecal Bacterial Community Fingerprinting of the Taiwanese Population and Underpinning of Potential Taxonomic Biomarkers.
Fang CY; Chen JS; Hsu BM; Hussain B; Rathod J; Lee KH
Microorganisms; 2021 Jul; 9(8):. PubMed ID: 34442626
[TBL] [Abstract][Full Text] [Related]
7. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
[TBL] [Abstract][Full Text] [Related]
8. SWATHtoMRM: Development of High-Coverage Targeted Metabolomics Method Using SWATH Technology for Biomarker Discovery.
Zha H; Cai Y; Yin Y; Wang Z; Li K; Zhu ZJ
Anal Chem; 2018 Mar; 90(6):4062-4070. PubMed ID: 29485856
[TBL] [Abstract][Full Text] [Related]
9. Specificity of metabolic colorectal cancer biomarkers in serum through effect size.
Di Giovanni N; Meuwis MA; Louis E; Focant JF
Metabolomics; 2020 Aug; 16(8):88. PubMed ID: 32789702
[TBL] [Abstract][Full Text] [Related]
10. Metabolomic Profiling Identified Serum Metabolite Biomarkers and Related Metabolic Pathways of Colorectal Cancer.
Zhang C; Zhou S; Chang H; Zhuang F; Shi Y; Chang L; Ai W; Du J; Liu W; Liu H; Zhou X; Wang Z; Hong T
Dis Markers; 2021; 2021():6858809. PubMed ID: 34917201
[TBL] [Abstract][Full Text] [Related]
11. Profiling the metabolic disorder and detection of colorectal cancer based on targeted amino acids metabolomics.
Yang Y; Wang Z; Li X; Lv J; Zhong R; Gao S; Zhang F; Chen W
J Transl Med; 2023 Nov; 21(1):824. PubMed ID: 37978537
[TBL] [Abstract][Full Text] [Related]
12. Global metabolomics profiling of colorectal cancer in Malaysian patients.
Amir Hashim NA; Ab-Rahim S; Wan Ngah WZ; Nathan S; Ab Mutalib NS; Sagap I; A Jamal AR; Mazlan M
Bioimpacts; 2021; 11(1):33-43. PubMed ID: 33469506
[No Abstract] [Full Text] [Related]
13. Combining NMR and LC/MS Using Backward Variable Elimination: Metabolomics Analysis of Colorectal Cancer, Polyps, and Healthy Controls.
Deng L; Gu H; Zhu J; Nagana Gowda GA; Djukovic D; Chiorean EG; Raftery D
Anal Chem; 2016 Aug; 88(16):7975-83. PubMed ID: 27437783
[TBL] [Abstract][Full Text] [Related]
14.
Lin Y; Ma C; Bezabeh T; Wang Z; Liang J; Huang Y; Zhao J; Liu X; Ye W; Tang W; Ouyang T; Wu R
Int J Cancer; 2019 Sep; 145(6):1679-1689. PubMed ID: 30720869
[TBL] [Abstract][Full Text] [Related]
15. Development of a Correlative Strategy To Discover Colorectal Tumor Tissue Derived Metabolite Biomarkers in Plasma Using Untargeted Metabolomics.
Wang Z; Cui B; Zhang F; Yang Y; Shen X; Li Z; Zhao W; Zhang Y; Deng K; Rong Z; Yang K; Yu X; Li K; Han P; Zhu ZJ
Anal Chem; 2019 Feb; 91(3):2401-2408. PubMed ID: 30580524
[TBL] [Abstract][Full Text] [Related]
16. Metabolomics for biomarker discovery in the diagnosis, prognosis, survival and recurrence of colorectal cancer: a systematic review.
Zhang F; Zhang Y; Zhao W; Deng K; Wang Z; Yang C; Ma L; Openkova MS; Hou Y; Li K
Oncotarget; 2017 May; 8(21):35460-35472. PubMed ID: 28389626
[TBL] [Abstract][Full Text] [Related]
17. Combination of GC-MS based metabolomics analysis with mouse xenograft models reveals a panel of dysregulated circulating metabolites and potential therapeutic targets for colorectal cancer.
Ni J; Chen Y; Li N; Sun D; Ju H; Chen Z
Transl Cancer Res; 2021 Apr; 10(4):1813-1825. PubMed ID: 35116504
[TBL] [Abstract][Full Text] [Related]
18. Urinary charged metabolite profiling of colorectal cancer using capillary electrophoresis-mass spectrometry.
Udo R; Katsumata K; Kuwabara H; Enomoto M; Ishizaki T; Sunamura M; Nagakawa Y; Soya R; Sugimoto M; Tsuchida A
Sci Rep; 2020 Dec; 10(1):21057. PubMed ID: 33273632
[TBL] [Abstract][Full Text] [Related]
19. Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection.
Ritchie SA; Ahiahonu PW; Jayasinghe D; Heath D; Liu J; Lu Y; Jin W; Kavianpour A; Yamazaki Y; Khan AM; Hossain M; Su-Myat KK; Wood PL; Krenitsky K; Takemasa I; Miyake M; Sekimoto M; Monden M; Matsubara H; Nomura F; Goodenowe DB
BMC Med; 2010 Feb; 8():13. PubMed ID: 20156336
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
